T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus

Leukemia

Volumn 22, Issue 3, 2008, Pages 608-619

  Hagenbeek, T J ^a,b,c   Spits, H ^a,b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; HERMES ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LCK; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INFILTRATION; CARCINOGENESIS; CONTROLLED STUDY; DEATH; GENE DELETION; GENE EXPRESSION; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; THYMOCYTE; THYMUS; THYMUS HYPERPLASIA;

EID: 40749131244     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405056     Document Type: Article

References (52)

1. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001; 114 (Part 8): 1439-1445.
2. Pallard C, Stegmann AP, van Kleffens T, Smart F, Venkitaraman A, Spits H. Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-mediated development of human thymocyte precursors. Immunity 1999; 10: 525-535.
3. Williams JA, Hathcock, KS, Klug D, Harada. Y, Choudloury B, Allison JP et al. Regulated costimulation in the thymus is critical for T cell development: Dysregulted CD28 costimulation can bypass the pre-TCR checkpoint. J Immunol 2005; 175: 4199-4207.
4. Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y et al T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001; 14: 523-534.
5. Deane JA, Fruman DA. Phosphoinositide 3-kinase: Diverse roles in immune cell activation. Annu Rev Immunol 2004; 22: 563-598.
6. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB et al Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol 1997; 7: 261-269.
7. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101.
8. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4: 648-657.
9. Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA, Boussiotis VA. Activation of P13K is indispensable for interleukin 7-mediated viability, proliferation,. glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med 2004; 200: 659-669.
10. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401: 82-85.
11. Kim K, Lee CK, Sayers TJ, Muegge K, Durum SK. The trophic action of IL-7 on pro-T cells: Inhibition of apoptosis of pro-T1, J2, and -T3 cells correlates with Bcl-2 and Bax levels and is independent of Fas and p53 pathways. J Immunol 1998; 160: 5735-5741.
12. Offner F, Plum J. The role of interleukin-7 in early T-cell development. Leuk Lymphoma 1998; 30: 87-99.
13. Rodewald HR, Waskow C, Haller C. Essential requirement for c-kit and common gamma chain in thymocyte development cannot be overruled by enforced expression of Bcl-2. J Exp Med 2001; 193: 1431-1437.
14. Ciofani M, Zuniga-Pflucker JC. Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nat Immunol 2005; 6: 881-888.
15. Taghon T, Yui MA, Pant R, Diamond RA, Rothenberg EV. Developmental and molecular characterization of emerging beta-and gammadelta-selected pre-T cells in the adult mouse thymus. Immunity 2006; 24: 53-64.
16. Mallick CA, Dudley EC, Viney JL, Owen MJ, Hayday AC. Rearrangement and diversity of T cell receptor beta chain genes in thymocytes: A critical role for the beta chain in development. Cell 1993; 73: 513-519.
17. von Boehmer H, Aifantis I, Feinberg J, Lechner O, Saint-Ruf C, Walter U et al. Pleiotropic changes controlled by the pre-T-cell receptor. Curr Opin Immunol 1999; 11: 135-142.
18. Hayes SM, Shores EW, Love PE. An architectural perspective on signaling by the pre-, alphabeta and gammadelta T cell receptors. Immunol Rev 2003; 191: 28-37.
19. Mao C, Tili EG, Dose M, Haks MC, Bear SE, Maroulakou I et al. Unequal contribution of Akt isoforms in the double-negative to double-positive thymocyte transition. J Immunol 2007; 178: 5443-5453.
20. Gomez M, Tybulewicz V, Cantrell DA. Control of pre-T cell proliferation and differentiation by the GTPase Rac-1. Nat Immunol 2000; 1 348-352.
21. Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. J Exp Med 1998; 188: 2301-2311.
22. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375-13378.
23. Suzuki A, de la Pompa JL, Stambolic Elia AJ, Sasaki T, del Barco Barrantes I et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998; 8: 1169-1178.
24. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten+/-mice. Science 1999; 285: 2122-2125.
25. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441: 475-482.
26. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM et al Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96: 1563-1568.
27. Uddin S, Hussain A, Al-Hussein K, Platanias LC, Bhatia KG. Inhibition of phosphatidylinositol 3′-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun 2004; 320: 932-938.
28. Hagenbeek TJ, Naspetti M, Malergue F, Garcon F, Nunes JA, Cleutjens KB et al. The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling. J Exp Med 2004; 200 883-894.
29. Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S, Makar KW et al A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 2001; 15: 763-774.
30. Marino S, Krimpenfort P, Leung C, van der Korput HA, Trapman J, Camenisch I et al. PTEN is essential for cell migration but not for late determination and tumourigenesis in the cerebellum. Development 2002; 129: 3513-3522.
31. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science 1994; 265: 103-106.
32. Kirberg J, Berns A, von Boehmer H. Peripheral T cell survival requires continual ligation of the T cell receptor to major histocompatibility complex-encoded molecules. J Exp Med 1997; 186: 1269-1275.
33. Gimeno R, Weijer K, Voordouw A, Uittenbogaart CH, Legrand N, Alves NL et al. Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/- gammac-/- mice: functional inactivation of p53 in developing T cells. Blood 2004; 104: 3886-3893.
34. Wiernik PH. HTLV-associated T-cell lymphoma and leukemia. In: Wiernik PH, Goldman JM, Dutcher JP, Kyle RA (eds). Neoplastic Diseases of the Blood, 4th edn. Cambridge University Press, The Edinburgh Building: Cambridge, UK, 2003, pp 156.
35. Naor D, Sionov RV, Ish-Shalom D. CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997; 71 241-319.
36. Rochman M, Moll J, Herrlich P, Wallach SB, Nedvetzki S, Sionov RV et al. The CD44 receptor of lymphoma cells: Structure-function relationships and mechanism of activation. Cell Adhes Commun 2000; 7: 331-347.
37. Zahalka MA, Okon E, Gosslar U, Holzmann B, Naor D. Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J Immunol 1995; 154: 5345-5355.
38. Geissinger E, Bonzheim I, Krenacs L, Roth S, Strobel P, Ott G et al Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies. J Mol Diagn 2005; 7: 455-464.
39. Sawada S, Scarborough JD, Killeen N, Littman DR. A lineage-specific transcriptional silencer regulates CD4 gene expression during T lymphocyte development. Cell 1994; 77: 917-929.
40. Na SY, Patra A, Scheuring Y, Marx A, Tolaini M, Kioussis D et al. Constitutively active protein kinase B enhances Lck and Erk activities and influences thymocyte selection and activation. J Immunol 2003; 171: 1285-1296.
41. Borlado LR, Redondo C, Alvarez B, Jimenez C, Criado LM, Flores J et al. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 2000; 14: 895-903.
42. Webb LM, Vigorito E, Wymann MP, Hirsch E, Turner M. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 2005; 175: 2783-2787.
43. Swat W, Montgrain V, Doggett TA, Douangpanya J, Puri K, Vermi W et al Essential role of P13Kdelta and P13Kgamma in thymocyte survival. Blood 2006; 107: 2415-2422.
44. Hernandez-Hoyos G, Sohn SJ, Rothenberg EV, Alberola-Ila J. Lck activity controls CD4/CD8 T cell lineage commitment. Immunity 2000; 12 313-322.
45. Rodriguez-Borlado L, Barber DF, Hernandez C, Rodriguez-Marcos MA, Sanchez A, Hirsch E et al. Phosphatidylinositol 3-kinase regulates the CD4/CD8 T cell differentiation ratio. J Immunol 2003; 170 4475-4482.
46. Malstrom S, Tili E, Kappes D, Ceci JD, Tsichlis PN. Tumor induction by an Lck-MyrAkt transgene is delayed by mechanisms controlling the size of the thymus. Proc Natl Acad Sci USA 2001; 98: 14967-14972.
47. Freeman D, Lesche R, Kertesz N, Wang S, Li G, Gao J et al. Genetic background controls tumor development in PTEN-deficient mice. Cancer Res 2006; 66: 6492-6496.
48. Trotman LC, Pandolfi PP. PTEN and p53: Who will get tke upper hand? Cancer Cell 2003; 3: 97-99.
49. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: Novel phosphoinositide phosphatases. Annu Rev Biochem 2001; 70: 247-279.
50. Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, Poggi V et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005; 106: 1400-1406.
51. Voll RE, Jimi E, Phillips RJ, Barber DF, Rincon M, Hayday AC et al NF-kappa B activation by the pre-T cell receptor serves as a selective survival signal in T lymphocyte development. Immunity 2000; 13: 677-689.
52. Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13: 70-77.